1399845-59-0

Basic information

• Product Name: methyl (4S,7S)-4-(5-(4-bromophenyl)-1H-imidazol-2-yl)-6,10-dioxooctahydro-1H-pyridazino[1,2-a][1,2]diazepin-7-ylcarbamate
• Synonyms: methyl (4S,7S)-4-(5-(4-bromophenyl)-1H-imidazol-2-yl)-6,10-dioxooctahydro-1H-pyridazino[1,2-a][1,2]diazepin-7-ylcarbamate
• CAS NO: 1399845-59-0
• Molecular Weight: 476.33
• Mol File: 1399845-59-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: methyl (4S,7S)-4-(5-(4-bromophenyl)-1H-imidazol-2-yl)-6,10-dioxooctahydro-1H-pyridazino[1,2-a][1,2]diazepin-7-ylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (4S,7S)-4-(5-(4-bromophenyl)-1H-imidazol-2-yl)-6,10-dioxooctahydro-1H-pyridazino[1,2-a][1,2]diazepin-7-ylcarbamate(1399845-59-0)
• EPA Substance Registry System: methyl (4S,7S)-4-(5-(4-bromophenyl)-1H-imidazol-2-yl)-6,10-dioxooctahydro-1H-pyridazino[1,2-a][1,2]diazepin-7-ylcarbamate(1399845-59-0)

Safety Data

• Hazardous Substances Data: 1399845-59-0(Hazardous Substances Data)

Upstream product

• 1399845-56-7 (1S,9S)-tert-butyl 9-(methoxycarbonylamino)-6,10-dioxooctahydro-1H-pyridazino[1,2-a][1,2]diazepine-1-carboxylate 
• 106928-72-7 (1S,9S)-t-butyl 1,2,3,4,7,8,9,10-octahydro-6,10-dioxo-9-phthalimidopyridazino<1,2-a><1,2>diazepine-1-carboxylate 
• 88767-96-8 (1S,9S)-t-butyl 9-amino-octahydro-6,10-dioxo-6H-pyridazino<1,2-a><1,2>diazepine-1-carboxylate 
• 1399845-58-9 methyl (4S,7S)-4-(2-(4-bromophenyl)-2-oxoethylcarbamoyl)-6,10-dioxooctahydro-1H-pyridazino[1,2-a][1,2]diazepin-7-ylcarbamate 
• 1399845-57-8 (1S,9S)-9-(methoxycarbonylamino)-6,10-dioxooctahydro-1H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid 

Downstream Products

• 1416718-18-7 {(4S,7S)-4-[5-(4'-{3-[(S)-1-((R)-2-Methoxycarbonylamino-2-phenyl-acetyl)-pyrrolidine-2-carbonyl]-ureido}-biphenyl-4-yl)-1H-imidazol-2-yl]-6,10-dioxo-octahydro-pyridazino[1,2-a][1,2]diazepin-7-yl}-carbamic acid methyl ester 
• 1430061-55-4 {(4S,7S)-4-[5-(4'-{2-[(S)-4,4-difluoro-1-((S)-2-methoxycarbonylamino-3-methylbutyryl)pyrrolidin-2-yl]-3H-imidazol-4-yl}biphenyl-4-yl)-1H-imidazol-2-yl]-6,10-dioxooctahydropyridazino[1,2-a][1,2]diazepin-7-yl}carbamic acid methyl ester 
• 1430061-57-6 {(4S,7S)-4-[5-(4'-{2-[(S)-1-((S)-2-methoxycarbonylamino-3-methylbutyryl)pyrrolidin-2-yl]-3H-imidazol-4-yl}biphenyl-4-yl)-1H-imidazol-2-yl]-6,10-dioxooctahydropyridazino[1,2-a][1,2]diazepin-7-yl}carbamic acid methyl ester 
• 1399845-60-3 methyl (4S,7S)-6,10-dioxo-4-(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-imidazol-2-yl)octahydro-1H-pyridazino[1,2-a][1,2]diazepin-7-ylcarbamate 

Relevant articles and documents

ANTIVIRAL COMPOUNDS

The present invention discloses compounds of Formulae I and II, wherein the variables in Formulae I and II are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formulae I and II in the treatment of HCV infection.

ANTIVIRAL COMPOUNDS

The present invention provides compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.